Literature DB >> 25312474

Clinical trial of a new technique for drugs of abuse testing: a new possible sampling technique.

Charlotte Skoglund1, Ulric Hermansson1, Olof Beck2.   

Abstract

Exhaled breath has recently been proposed as a matrix for drug testing. This study aims to further explore, develop and validate exhaled breath as a safe and effective non-invasive method for drug testing in a clinical setting. Self-reported drug use was recorded and drug testing was performed by mass spectrometry and immunochemical methods using breath, plasma and urine samples from 45 individuals voluntarily seeking treatment for recreational drug use. Cannabis was the most prevalent drug detected by any method. Urine sampling detected most cases. The exhaled breath technique was less sensitive (73%) than plasma analysis for detection of cannabis uses but captures a more recent drug intake than both plasma and urine. Exhaled breath was the preferred specimen to donate according to interview data of the participants. Testing illicit drugs with the exhaled breath sampling technique is a sufficient, non-invasive and safe alternative and complement to plasma and/or urine sampling.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cannabis; Drug testing; Exhaled breath; Illicit drugs; Self-report

Mesh:

Substances:

Year:  2014        PMID: 25312474     DOI: 10.1016/j.jsat.2014.09.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  2 in total

1.  Pharmacokinetics of methylphenidate and ritalinic acid in plasma correlations with exhaled breath and oral fluid in healthy volunteers.

Authors:  Michel Arvidsson; Marja-Liisa Dahl; Olof Beck; Gerd Ackehed; Karin Nordin; Staffan Rosenborg
Journal:  Eur J Clin Pharmacol       Date:  2019-11-30       Impact factor: 2.953

2.  SARS-CoV-2: Viral Loads of Exhaled Breath and Oronasopharyngeal Specimens in Hospitalized Patients with COVID-19.

Authors:  Madiha Malik; Ann-Cathrin Kunze; Thomas Bahmer; Stefan Herget-Rosenthal; Thomas Kunze
Journal:  Int J Infect Dis       Date:  2021-07-06       Impact factor: 3.623

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.